Business Context and Reporting Period
Xtant Medical Holdings, Inc. (XTNT) filed this Form 8-K on January 15, 2026, reporting events related to the divestiture of its Coflex/CoFix products and Paradigm Spine GmbH. The filing details amendments to payment terms originally established in December 2025.
Key Financial Metrics and Transaction Details
- Total Purchase Price (Coflex/CoFix): $17.5 million (subject to inventory adjustment).
- Total Purchase Price (Paradigm Spine GmbH): $1.7 million (subject to working capital adjustments).
- Debt Instrument: An unsecured promissory note of $8.2 million was issued by the buyer, Companion Spine, as part of the Coflex/CoFix consideration.
- Estimated Adjustment Payment: $1,742,000 related to the Paradigm Spine GmbH sale.
Material Changes and Amendments
On January 15, 2026, the Company amended the terms of the divestiture agreements with Companion Spine:
- Note Maturity Extension: The maturity date of the $8.2 million promissory note was extended from January 15, 2026, to January 31, 2026.
- Payment Timing Adjustment: The payment of the estimated $1,742,000 positive purchase price adjustment for the Paradigm Spine GmbH sale was rescheduled from January 15, 2026, to January 31, 2026.
Outlook, Risks, and Contingencies
The filing notes that the purchase prices for both divestitures remain subject to adjustments. Specifically, any decrease in the purchase price due to adjustments would reduce the principal amount of the $8.2 million Note. The filing does not provide updated revenue guidance or liquidity metrics beyond the specific transaction amendments.
Key Facts for Investor Verification
- Verify the final closing inventory valuation for the Coflex/CoFix divestiture to confirm the ultimate principal amount of the $8.2 million Note.
- Confirm the final net working capital and cash adjustments for the Paradigm Spine GmbH sale to validate the $1,742,000 payment amount.
- Monitor the receipt of the extended payments scheduled for January 31, 2026.